0000862861--12-27 2025 Q1 false 0.0083 xbrli:shares iso4217:USD iso4217:USD xbrli:shares jan:segment xbrli:pure jan:patent jan:debenture jan:investor jan:addition jan:officer jan:payment jan:landlord jan:guarantee utr:sqft jan:seller jan:promissory_note 0000862861 2024-12-29 2025-03-29 0000862861 2025-05-07 0000862861 2025-03-29 0000862861 2024-12-28 0000862861 us-gaap:RelatedPartyMember 2025-03-29 0000862861 us-gaap:RelatedPartyMember 2024-12-28 0000862861 us-gaap:NonrelatedPartyMember 2025-03-29 0000862861 us-gaap:NonrelatedPartyMember 2024-12-28 0000862861 jan:SeriesSConvertiblePreferredStockMember 2024-12-28 0000862861 jan:SeriesSConvertiblePreferredStockMember 2025-03-29 0000862861 us-gaap:SeriesAPreferredStockMember 2025-03-29 0000862861 us-gaap:SeriesAPreferredStockMember 2024-12-28 0000862861 us-gaap:SeriesBPreferredStockMember 2024-12-28 0000862861 us-gaap:SeriesBPreferredStockMember 2025-03-29 0000862861 jan:SeriesIConvertiblePreferredStockMember 2024-12-28 0000862861 jan:SeriesIConvertiblePreferredStockMember 2025-03-29 0000862861 jan:SeriesMPreferredStockMember 2025-03-29 0000862861 jan:SeriesMPreferredStockMember 2024-12-28 0000862861 jan:SeriesQConvertiblePreferredStockMember 2024-12-28 0000862861 jan:SeriesQConvertiblePreferredStockMember 2025-03-29 0000862861 jan:SeriesVConvertiblePreferredStockMember 2024-12-28 0000862861 jan:SeriesVConvertiblePreferredStockMember 2025-03-29 0000862861 2023-12-31 2024-03-30 0000862861 2023-12-30 0000862861 2024-03-30 0000862861 us-gaap:PreferredStockMember jan:SeriesA1PreferredStockMember 2024-12-28 0000862861 us-gaap:PreferredStockMember jan:SeriesS1PreferredMember 2024-12-28 0000862861 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2024-12-28 0000862861 us-gaap:PreferredStockMember jan:SeriesIPreferredStockMember 2024-12-28 0000862861 us-gaap:PreferredStockMember jan:SeriesMPreferredStockMember 2024-12-28 0000862861 us-gaap:PreferredStockMember jan:SeriesQPreferredStockMember 2024-12-28 0000862861 us-gaap:PreferredStockMember jan:SeriesVPreferredStockMember 2024-12-28 0000862861 us-gaap:CommonStockMember 2024-12-28 0000862861 us-gaap:AdditionalPaidInCapitalMember 2024-12-28 0000862861 us-gaap:RetainedEarningsMember 2024-12-28 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-28 0000862861 us-gaap:NoncontrollingInterestMember 2024-12-28 0000862861 us-gaap:CommonStockMember 2024-12-29 2025-03-29 0000862861 us-gaap:AdditionalPaidInCapitalMember 2024-12-29 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesVPreferredStockMember 2024-12-29 2025-03-29 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-29 2025-03-29 0000862861 us-gaap:RetainedEarningsMember 2024-12-29 2025-03-29 0000862861 us-gaap:NoncontrollingInterestMember 2024-12-29 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesA1PreferredStockMember 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesS1PreferredMember 2025-03-29 0000862861 us-gaap:PreferredStockMember us-gaap:SeriesBPreferredStockMember 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesIPreferredStockMember 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesMPreferredStockMember 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesQPreferredStockMember 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesVPreferredStockMember 2025-03-29 0000862861 us-gaap:CommonStockMember 2025-03-29 0000862861 us-gaap:AdditionalPaidInCapitalMember 2025-03-29 0000862861 us-gaap:RetainedEarningsMember 2025-03-29 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-29 0000862861 us-gaap:NoncontrollingInterestMember 2025-03-29 0000862861 us-gaap:PreferredStockMember jan:SeriesA1PreferredStockMember 2023-12-30 0000862861 us-gaap:PreferredStockMember jan:SeriesS1PreferredMember 2023-12-30 0000862861 us-gaap:CommonStockMember 2023-12-30 0000862861 us-gaap:AdditionalPaidInCapitalMember 2023-12-30 0000862861 us-gaap:RetainedEarningsMember 2023-12-30 0000862861 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 2024-03-30 0000862861 us-gaap:CommonStockMember 2023-12-31 2024-03-30 0000862861 us-gaap:RetainedEarningsMember 2023-12-31 2024-03-30 0000862861 us-gaap:PreferredStockMember jan:SeriesA1PreferredStockMember 2024-03-30 0000862861 us-gaap:PreferredStockMember jan:SeriesS1PreferredMember 2024-03-30 0000862861 us-gaap:CommonStockMember 2024-03-30 0000862861 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0000862861 us-gaap:RetainedEarningsMember 2024-03-30 0000862861 jan:QodenTechnologiesLLCMember 2024-11-08 2024-11-08 0000862861 jan:SeriesQConvertiblePreferredStockMember jan:QodenTechnologiesLLCMember 2024-11-08 2024-11-08 0000862861 jan:QodenTechnologiesLLCMember 2024-11-08 0000862861 jan:Alt5SigmaInc.Member 2024-05-15 2024-05-15 0000862861 jan:Alt5SigmaInc.Member 2024-05-15 0000862861 jan:Alt5SigmaInc.Member 2024-05-09 0000862861 jan:Alt5SigmaInc.Member us-gaap:SeriesBPreferredStockMember 2024-05-15 2024-05-15 0000862861 jan:Alt5SigmaInc.Member jan:SeriesMPreferredStockMember 2024-05-15 2024-05-15 0000862861 jan:Alt5SigmaInc.Member us-gaap:CommonStockMember 2024-05-15 2024-05-15 0000862861 jan:Alt5SigmaInc.Member 2023-12-31 2024-12-28 0000862861 jan:Alt5SigmaInc.Member us-gaap:CustomerRelationshipsMember 2024-05-15 0000862861 jan:Alt5SigmaInc.Member us-gaap:TradeNamesMember 2024-05-15 0000862861 jan:Alt5SigmaInc.Member us-gaap:DevelopedTechnologyRightsMember 2024-05-15 0000862861 us-gaap:AssetUnderConstructionMember 2025-03-29 0000862861 us-gaap:AssetUnderConstructionMember 2024-12-28 0000862861 jan:SoinIntangiblesMember 2025-03-29 0000862861 jan:SoinIntangiblesMember 2024-12-28 0000862861 jan:CryptocurrencyExchangeSoftwareIntangibleMember 2025-03-29 0000862861 jan:CryptocurrencyExchangeSoftwareIntangibleMember 2024-12-28 0000862861 jan:PatentsAndDomainsMember 2025-03-29 0000862861 jan:PatentsAndDomainsMember 2024-12-28 0000862861 us-gaap:TradeNamesMember 2025-03-29 0000862861 us-gaap:TradeNamesMember 2024-12-28 0000862861 us-gaap:CustomerRelationshipsMember 2025-03-29 0000862861 us-gaap:CustomerRelationshipsMember 2024-12-28 0000862861 us-gaap:DevelopedTechnologyRightsMember 2025-03-29 0000862861 us-gaap:DevelopedTechnologyRightsMember 2024-12-28 0000862861 jan:QodenIntangibleMember jan:QodenTechnologiesLLCMember 2024-11-08 0000862861 jan:ALT5SubsidiaryMember us-gaap:TradeNamesMember 2024-05-14 0000862861 jan:ALT5SubsidiaryMember us-gaap:CustomerRelationshipsMember 2024-05-14 0000862861 jan:ALT5SubsidiaryMember us-gaap:DevelopedTechnologyRightsMember 2024-05-14 0000862861 jan:SoinIntangiblesMember 2022-12-28 0000862861 jan:A12DebenturesMaturingJune302025Member jan:DebenturesMember 2024-12-28 0000862861 jan:A12DebenturesMaturingJune302025Member jan:DebenturesMember 2025-03-29 0000862861 jan:DebenturesMember 2025-03-29 0000862861 jan:DebenturesMember 2024-12-28 0000862861 jan:DebenturesMember 2018-10-01 2019-09-30 0000862861 jan:LegacySubsidiaryFixedDepositsMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:LegacySubsidiaryFixedDepositsMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:LegacySubsidiaryLoanMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:LegacySubsidiaryLoanMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:LegacyUnaffiliatedThirdPartyNotesMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:LegacyUnaffiliatedThirdPartyNotesMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:OtherLegacyNotesPayableMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:OtherLegacyNotesPayableMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:LegacySubsidiaryFixedDepositsMember jan:ALT5SubsidiaryMember jan:FixedDepositsMember 2025-03-29 0000862861 jan:LegacySubsidiaryFixedDepositsMember jan:ALT5SubsidiaryMember jan:FixedDepositsMember srt:MinimumMember 2025-03-29 0000862861 jan:LegacySubsidiaryFixedDepositsMember jan:ALT5SubsidiaryMember jan:FixedDepositsMember srt:MaximumMember 2025-03-29 0000862861 jan:LegacySubsidiaryFixedDepositsMember jan:ALT5SubsidiaryMember jan:FixedDepositsMember 2024-12-29 2025-03-29 0000862861 jan:LegacySubsidiaryFixedDepositsMember jan:ALT5SubsidiaryMember jan:FixedDepositsMember 2024-12-28 0000862861 jan:LegacySubsidiaryLoanMember us-gaap:LoansPayableMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:LegacySubsidiaryLoanMember us-gaap:LoansPayableMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:IcgNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2024-02-07 0000862861 jan:IcgNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2023-12-31 2024-12-28 0000862861 jan:IcgNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2025-03-29 0000862861 jan:IcgNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2024-12-28 0000862861 jan:LiveNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2024-02-07 0000862861 jan:LiveNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2023-12-31 2024-12-28 0000862861 jan:LiveNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2025-03-29 0000862861 jan:LiveNoteMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2024-12-28 0000862861 jan:NonConvertibleDebentureBigDebentureMember us-gaap:UnsecuredDebtMember 2024-08-20 0000862861 jan:NonConvertibleDebentureBigDebentureMember us-gaap:UnsecuredDebtMember jan:InvestorOneMember 2024-08-20 0000862861 jan:BigWarrantMember jan:InvestorOneMember 2024-08-20 0000862861 jan:NonConvertibleDebentureSmallDebentureMember us-gaap:UnsecuredDebtMember jan:InvestorTwoAndInvestorThreeMember 2024-08-20 0000862861 us-gaap:WarrantMember jan:InvestorTwoAndInvestorThreeMember 2024-08-20 0000862861 jan:NonConvertibleDebentureBigAndSmallDebentureMember us-gaap:UnsecuredDebtMember jan:DebtInstrumentCovenantPeriodPeriodOneMember 2024-08-20 0000862861 jan:NonConvertibleDebentureBigAndSmallDebentureMember us-gaap:UnsecuredDebtMember jan:DebtInstrumentCovenantPeriodPeriodTwoMember 2024-08-20 0000862861 jan:NonConvertibleDebentureBigAndSmallDebentureMember us-gaap:UnsecuredDebtMember jan:DebtInstrumentCovenantPeriodPeriodThreeMember 2024-08-20 0000862861 jan:DebtInstrumentOriginalIssueDiscountExpansionOneMember jan:NonConvertibleDebentureBigDebentureMember us-gaap:UnsecuredDebtMember 2024-08-20 0000862861 jan:DebtInstrumentOriginalIssueDiscountExpansionTwoMember jan:NonConvertibleDebentureBigDebentureMember us-gaap:UnsecuredDebtMember 2024-08-20 0000862861 jan:NonConvertibleDebentureSmallDebentureMember us-gaap:UnsecuredDebtMember 2024-08-20 0000862861 jan:DebtInstrumentOriginalIssueDiscountExpansionOneMember jan:NonConvertibleDebentureSmallDebentureMember us-gaap:UnsecuredDebtMember 2024-08-20 0000862861 jan:DebtInstrumentOriginalIssueDiscountExpansionTwoMember jan:NonConvertibleDebentureSmallDebentureMember us-gaap:UnsecuredDebtMember 2024-08-20 0000862861 jan:BigWarrantMember 2024-08-20 0000862861 jan:BigWarrantMember jan:DebtInstrumentCovenantPeriodPeriodOneMember 2024-08-20 0000862861 jan:BigWarrantMember jan:DebtInstrumentCovenantPeriodPeriodTwoMember 2024-08-20 0000862861 jan:BigWarrantMember jan:DebtInstrumentCovenantPeriodPeriodThreeMember 2024-08-20 0000862861 jan:SmallWarrantMember 2024-08-20 0000862861 jan:SmallWarrantMember jan:DebtInstrumentCovenantPeriodPeriodOneMember 2024-08-20 0000862861 jan:SmallWarrantMember jan:DebtInstrumentCovenantPeriodPeriodTwoMember 2024-08-20 0000862861 jan:SmallWarrantMember jan:DebtInstrumentCovenantPeriodPeriodThreeMember 2024-08-20 0000862861 2024-08-20 2024-08-20 0000862861 jan:NonConvertibleDebentureSmallDebentureMember 2024-12-29 2025-03-29 0000862861 jan:BigWarrantMember us-gaap:RelatedPartyMember 2024-09-29 2024-12-28 0000862861 jan:SmallWarrantMember us-gaap:RelatedPartyMember 2024-09-29 2024-12-28 0000862861 jan:NonConvertibleDebentureBigAndSmallDebentureMember us-gaap:UnsecuredDebtMember 2024-09-29 2024-12-28 0000862861 jan:NonConvertibleDebentureBigAndSmallDebentureMember us-gaap:UnsecuredDebtMember 2024-12-29 2025-03-29 0000862861 jan:NonConvertibleDebentureBigAndSmallDebentureMember us-gaap:UnsecuredDebtMember 2025-03-29 0000862861 jan:NonConvertibleDebentureBigAndSmallDebentureMember us-gaap:UnsecuredDebtMember 2024-12-28 0000862861 jan:FixedDepositAgreementMember jan:FixedDepositsMember jan:ALT5SubsidiaryMember 2024-09-19 2024-09-19 0000862861 jan:FixedDepositAgreementMember jan:FixedDepositsMember jan:ALT5SubsidiaryMember 2024-09-19 0000862861 jan:FixedDepositAgreementMember jan:FixedDepositsMember jan:ALT5SubsidiaryMember 2025-03-29 0000862861 jan:FixedDepositAgreementMember jan:FixedDepositsMember jan:ALT5SubsidiaryMember 2024-12-28 0000862861 jan:PersonalFixedDepositAgreementMember jan:FixedDepositsMember jan:ALT5SubsidiaryMember 2025-02-01 2025-02-01 0000862861 jan:PersonalFixedDepositAgreementMember jan:FixedDepositsMember jan:ALT5SubsidiaryMember 2025-02-01 0000862861 jan:PersonalFixedDepositAgreementMember jan:FixedDepositsMember jan:ALT5SubsidiaryMember 2025-03-29 0000862861 jan:NotePayableToIsaacCapitalGroupMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:NotePayableToIsaacCapitalGroupMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:NotePayableToLiveVentureIncorporatedMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:NotePayableToLiveVentureIncorporatedMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:IsaacCapitalGroupShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:IsaacCapitalGroupShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 jan:NovalkAppsSAALLPShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:NovalkAppsSAALLPShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember 2024-12-28 0000862861 us-gaap:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember 2025-03-29 0000862861 us-gaap:RelatedPartyMember us-gaap:NotesPayableOtherPayablesMember 2024-12-28 0000862861 jan:NotesPayableRelatedPartiesMember us-gaap:RelatedPartyMember 2025-03-29 0000862861 jan:IcgNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2024-02-07 0000862861 jan:IcgNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2024-12-29 2025-03-29 0000862861 jan:IcgNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember us-gaap:EquityUnitPurchaseAgreementsMember jan:IcgNoteMember 2024-12-29 2025-03-29 0000862861 jan:IcgNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2024-12-28 0000862861 jan:IcgNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2025-03-29 0000862861 jan:IsaacCapitalGroupShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2024-04-18 2024-04-18 0000862861 jan:IsaacCapitalGroupShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2024-04-18 0000862861 jan:IsaacCapitalGroupShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2025-03-29 0000862861 jan:IsaacCapitalGroupShortTermDemandAdvanceMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:IcgNoteMember 2024-12-28 0000862861 jan:LiveNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:LiveVentureIncorporatedMember 2024-02-07 0000862861 jan:LiveNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:LiveVentureIncorporatedMember 2024-12-29 2025-03-29 0000862861 jan:LiveNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember us-gaap:EquityUnitPurchaseAgreementsMember jan:LiveVentureIncorporatedMember 2024-12-29 2025-03-29 0000862861 jan:LiveNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:LiveVentureIncorporatedMember 2024-12-28 0000862861 jan:LiveNoteMember us-gaap:NotesPayableOtherPayablesMember us-gaap:RelatedPartyMember jan:LiveVentureIncorporatedMember 2025-03-29 0000862861 us-gaap:RelatedPartyMember jan:NovalkAppsSAALLPMember jan:RelatedPartyTransactionShortTermAdvancesMember 2024-05-28 2024-05-28 0000862861 us-gaap:RelatedPartyMember jan:NovalkAppsSAALLPMember jan:RelatedPartyTransactionShortTermAdvancesMember 2024-06-03 2024-06-03 0000862861 us-gaap:RelatedPartyMember jan:NovalkAppsSAALLPMember jan:RelatedPartyTransactionShortTermAdvancesMember 2024-05-28 0000862861 us-gaap:RelatedPartyMember jan:NovalkAppsSAALLPMember jan:RelatedPartyTransactionShortTermAdvancesMember 2024-06-03 0000862861 us-gaap:RelatedPartyMember jan:NovalkAppsSAALLPMember jan:RelatedPartyTransactionShortTermAdvancesMember 2024-12-28 0000862861 us-gaap:RelatedPartyMember jan:NovalkAppsSAALLPMember jan:RelatedPartyTransactionShortTermAdvancesMember 2025-03-29 0000862861 jan:SECComplaintMember 2021-08-02 0000862861 jan:SECComplaintMember 2024-05-28 2024-05-28 0000862861 jan:SECComplaintMember 2024-05-28 0000862861 jan:Main270LLCLitigationMember 2024-12-29 2025-03-29 0000862861 jan:Main270LLCLitigationMember jan:ApplianceSmartIncMember 2024-12-29 2025-03-29 0000862861 jan:OtherCommitmentsAndLitigationCasesMember 2022-01-01 0000862861 jan:OtherCommitmentsAndLitigationCasesMember 2017-12-30 0000862861 jan:OtherCommitmentsAndLitigationCasesMember 2024-12-28 0000862861 jan:ArticlesOfIncorporationMember 2025-03-29 0000862861 2025-01-15 2025-01-15 0000862861 jan:SeriesVConvertiblePreferredStockMember 2024-05-04 2024-05-04 0000862861 jan:SeriesVConvertiblePreferredStockMember 2025-03-12 0000862861 jan:A2024EquityIncentivePlanMember 2025-03-29 0000862861 jan:A2024EquityIncentivePlanMember 2024-12-29 2025-03-29 0000862861 jan:A2023EquityIncentivePlanMember 2025-03-29 0000862861 us-gaap:RestrictedStockUnitsRSUMember jan:A2023EquityIncentivePlanMember 2024-12-29 2025-03-29 0000862861 us-gaap:RestrictedStockUnitsRSUMember jan:A2023EquityIncentivePlanMember 2023-12-31 2024-03-30 0000862861 jan:Plan2016Member 2020-11-03 0000862861 jan:Plan2016Member 2020-11-04 0000862861 jan:Plan2016Member 2025-03-29 0000862861 jan:Plan2016Member 2024-12-28 0000862861 jan:Plan2011Member 2025-03-29 0000862861 jan:Plan2011Member 2024-12-28 0000862861 jan:Plan2011Member 2024-12-29 2025-03-29 0000862861 2023-12-31 2024-12-28 0000862861 us-gaap:EmployeeStockOptionMember 2024-12-29 2025-03-29 0000862861 us-gaap:EmployeeStockOptionMember 2023-12-31 2024-03-30 0000862861 jan:SeriesA1ConvertiblePreferredStockMember 2025-03-29 0000862861 jan:SeriesA1ConvertiblePreferredStockMember 2024-12-29 2025-03-29 0000862861 jan:SeriesA1ConvertiblePreferredStockMember 2024-12-28 0000862861 jan:SeriesIConvertiblePreferredStockMember 2024-12-29 2025-03-29 0000862861 jan:SeriesQConvertiblePreferredStockMember 2024-12-29 2025-03-29 0000862861 jan:SoinTherapeuticsLLCMember jan:SeriesSConvertiblePreferredStockMember 2022-12-28 0000862861 jan:SoinTherapeuticsLLCMember jan:SeriesSConvertiblePreferredStockMember 2022-12-28 2022-12-28 0000862861 jan:SeriesSConvertiblePreferredStockMember 2024-12-29 2025-03-29 0000862861 jan:SeriesVConvertiblePreferredStockMember 2024-12-29 2025-03-29 0000862861 jan:SeriesVConvertiblePreferredStockMember 2024-05-04 0000862861 us-gaap:SegmentContinuingOperationsMember 2024-12-29 2025-03-29 0000862861 us-gaap:SegmentContinuingOperationsMember 2023-12-31 2024-03-30 0000862861 jan:FintechMember 2024-12-29 2025-03-29 0000862861 jan:FintechMember 2023-12-31 2024-03-30 0000862861 jan:BiotechnologyMember 2024-12-29 2025-03-29 0000862861 jan:BiotechnologyMember 2023-12-31 2024-03-30 0000862861 us-gaap:CorporateAndOtherMember 2024-12-29 2025-03-29 0000862861 us-gaap:CorporateAndOtherMember 2023-12-31 2024-03-30 0000862861 us-gaap:RelatedPartyMember jan:LiveVenturesIncorporatedMember 2024-12-29 2025-03-29 0000862861 us-gaap:RelatedPartyMember jan:LiveVenturesIncorporatedMember 2023-12-31 2024-03-30 0000862861 us-gaap:RelatedPartyMember jan:LiveVenturesIncorporatedMember 2025-03-29 0000862861 jan:LiveVenturesAndICGNotesMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2024-02-07 0000862861 jan:LiveVenturesAndICGNotesMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2024-12-28 0000862861 jan:LiveVenturesAndICGNotesMember jan:PromissoryNoteMember us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember 2025-03-29 0000862861 jan:MswipeTransactionMember us-gaap:SubsequentEventMember jan:ThreeSellersMember 2025-05-09 2025-05-09 0000862861 jan:MswipeTransactionMember us-gaap:SubsequentEventMember jan:ThreeSellersMember 2025-05-09 0000862861 jan:MswipeTransactionMember us-gaap:SubsequentEventMember jan:TwoOfTheSellersMember 2025-05-09 0000862861 jan:MswipeTransactionMember us-gaap:SubsequentEventMember jan:TwoOfTheSellersMember 2025-05-09 2025-05-09 0000862861 jan:MswipeTransactionMember us-gaap:SubsequentEventMember 2025-05-09 0000862861 jan:MswipeTransactionMember us-gaap:SubsequentEventMember 2025-05-09 2025-05-09
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended March 29, 2025
or
o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File No. 0-19621
ALT5 SIGMA CORPORATION
(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation or organization) |  | 41-1454591 (I.R.S. Employer Identification No.)
325 E. Warm Springs Road, Suite 102 Las Vegas, Nevada (Address of principal executive offices) |  | 89119 (Zip Code)

702-997-5968
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.001 par value per share |  | ALTS |  | The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. x Yes o No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer | o |  | Accelerated filer | o
Non-accelerated filer | x |  | Smaller reporting company | x
Emerging growth company | o |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). o Yes x No
As of May 7, 2025, there were 17,454,660 outstanding shares of the registrant’s common stock, with a par value of $0.001.

Table of Contents
ALT5 SIGMA CORPORATION
INDEX TO FORM 10-Q

|  | Page
PART I. FINANCIAL INFORMATION |
Item 1. | Condensed Consolidated Financial Statements | 3
| Unaudited Condensed Consolidated Balance Sheets as of March 29, 202 5 and December 28, 202 4 | 4
| Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income for the 13 weeks ended March 29, 202 5 and March 30, 202 4 | 5
| Unaudited Condensed Consolidated Statements of Cash Flows for the 13 weeks ended March 29, 202 5 and March 30, 202 4 | 6
| Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the 13 weeks ended March 29, 202 5 and March 30, 202 4 | 7
| Notes to Unaudited Condensed Consolidated Financial Statements | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 30
Item 4. | Controls and Procedures | 30
PART II. OTHER INFORMATION |
Item 1. | Legal Proceedings | 32
Item 1A. | Risk Factors | 32
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 32
Item 3. | Defaults Upon Senior Securities | 32
Item 4. | Mine Safety Disclosures | 32
Item 5 | Other Information | 32
Item 6. | Exhibits | 32
SIGNATURES | 35

2

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements
3

Table of Contents
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per-share amounts)

| March 29, 2025 |  | December 28, 2024
| (Unaudited) |  |
Assets |  |  |
Cash | $ | 10,811 |  |  | $ | 7,177 |
Trade and other receivables, net | 5,166 |  |  | 2,530 |
Digital assets receivable | 14,545 |  |  | 23,776 |
Prepaid expenses and other current assets | 1,273 |  |  | 1,518 |
Total current assets | 31,795 |  |  | 35,001 |
Property and equipment, net | 1,170 |  |  | 1,170 |
Right of use assets | 116 |  |  | 121 |
Intangible assets, net | 33,220 |  |  | 34,430 |
Goodwill | 11,714 |  |  | 11,714 |
Total assets | $ | 78,015 |  |  | $ | 82,436 |
Liabilities and Stockholders' Equity |  |  |
Liabilities: |  |  |
Accounts payable | $ | 2,901 |  |  | $ | 3,231 |
Accrued liabilities - other | 2,860 |  |  | 2,553 |
Digital assets payable | 25,192 |  |  | 30,918 |
Due to Soin | 2,500 |  |  | 2,850 |
Convertible debentures | 563 |  |  | 563 |
Operating lease liabilities | 18 |  |  | 10 |
Notes payable | 3,334 |  |  | — |
Related party notes payable and advances | 827 |  |  | 812 |
Total current liabilities | 38,195 |  |  | 40,937 |
Deferred income taxes, net | 1,041 |  |  | 1,041 |
Notes payable | 9,419 |  |  | 11,570 |
Operating lease liabilities | 107 |  |  | 113 |
Other noncurrent liabilities | 67 |  |  | 108 |
Total liabilities | 48,829 |  |  | 53,769 |
Commitments and contingencies (Note 9) |  |  |
Mezzanine equity |  |  |
Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 shares issued and outstanding at March 29, 2025 and December 28, 2024 | 3,856 |  |  | 3,856 |
Stockholders' equity: |  |  |
Preferred stock, series A - par value $0.001 per share 2,000,000 authorized, 23,480 shares issued and outstanding at March 29, 2025 and December 28, 2024 | — |  |  | — |
Preferred stock, series B - par value$0.001 per share, 34,250 authorized, 34,207 shares issued and outstanding at March 29, 2025 and December 28, 2024 | 8,552 |  |  | 8,552 |
Convertible preferred stock, series I - par value $0.001 per share, 2,000,000 authorized, 17,000 shares issued and outstanding at March 29, 2025 and December 28, 2024 | — |  |  | — |
Preferred stock, series M - par value $0.001 per share, 3,200 authorized, 3,200 shares issued and outstanding at March 29, 2025 and December 28, 2024 | — |  |  | — |
Preferred stock, series Q - par value $0.001 per share, 2,000,000 authorized, 925,212 shares issued and outstanding at March 29, 2025 and December 28, 2024 | 1,321 |  |  | 1,321 |
Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at March 29, 2025 and December 28, 2024, respectively | 7,993 |  |  | 7,993 |
Convertible preferred stock, series V - par value $0.001 per share, 125,000 authorized, 0 and 5,000 shares issued and outstanding at March 29, 2025 and December 28, 2024, respectively | — |  |  | — |
Common stock, par value $0.001 per share, 200,000,000 shares authorized,16,078,647 and 15,417,693 shares issued and outstanding at March 29, 2025 and at December 28, 2024, respectively | 9 |  |  | 9 |
Accumulated other comprehensive loss | 1,316 |  |  | (2,317) |
Additional paid-in capital | 62,379 |  |  | 62,207 |
Accumulated deficit | (59,740) |  |  | (56,879) |
Equity attributable to ALT5 Sigma Corporation shareholders | 21,830 |  |  | 20,886 |
Noncontrolling interest | $ | 3,500 |  |  | $ | 3,925 |
Total liabilities and stockholders' equity | $ | 78,015 |  |  | $ | 82,436 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

Table of Contents
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(UNAUDITED)
(Dollars in thousands, except per-share)

| For the Thirteen Weeks Ended
| March 29, 2025 |  | March 30, 2024
Revenues | $ | 5,514 |  |  | $ | — |
Cost of revenues | 2,923 |  |  | — |
Gross profit | 2,591 |  |  | — |
Operating expenses: |  |  |
Selling, general and administrative expenses | 4,761 |  |  | 1,806 |
Operating loss | (2,170) |  |  | (1,806) |
Other income (expense): |  |  |
Interest income (expense), net | (720) |  |  | (252) |
Unrealized gain on exchange transactions | 87 |  |  | — |
Realized gain on exchange transactions | 308 |  |  | — |
Unrealized loss on marketable securities | — |  |  | (190) |
Other income, net | (81) |  |  | 29 |
Total other expense, net | (406) |  |  | (413) |
Loss before provision for income taxes | (2,576) |  |  | (2,219) |
Income tax provision (benefit) | 285 |  |  | (75) |
Net loss | $ | (2,861) |  |  | $ | (2,144) |
Net loss per share: |  |  |
Net loss per share, basic and diluted | $ | (0.18) |  |  | $ | (0.34) |
Weighted average common shares outstanding: |  |  |
Basic | 15,550,706 |  | 6,308,331
Diluted | 15,550,706 |  | 6,308,331

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

Table of Contents
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)

| For the Thirteen Weeks Ended
| March 29, 2025 |  | March 30, 2024
OPERATING ACTIVITIES: |  |  |
Net loss from continuing operations | $ | (2,861) |  |  | $ | (2,144) |
Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
Depreciation and amortization | 1,210 |  |  | 639 |
Stock based compensation expense | — |  |  | 345 |
Noncash expense for professional services | 47 |  |  | — |
Unrealized loss on marketable securities | — |  |  | 190 |
Related party notes issued for shared services | — |  |  | 600 |
Amortization of ROU assets | 39 |  |  | — |
Unrealized gain on digital assets | 87 |  |  | — |
Realized gain on digital assets | 308 |  |  | — |
Change in deferred tax liability | — |  |  | (75) |
Changes in assets and liabilities: |  |  |
Accounts receivable | (2,711) |  |  | (149) |
Digital assets receivable | 9,231 |  |  | — |
Prepaid expenses and other current assets | 292 |  |  | 7 |
Accounts payable and accrued expenses | (332) |  |  | 33 |
Digital assets payable | (6,853) |  |  | — |
Deposits and other assets | — |  |  | 10 |
Net cash used in operating activities | (1,543) |  |  | (544) |
INVESTING ACTIVITIES: |  |  |
Net cash used in investing activities | — |  |  | — |
FINANCING ACTIVITIES: |  |  |
Proceeds from equity financing, net | — |  |  | 600 |
Proceeds from the issuance of notes payable | 1,598 |  |  | — |
Payments on notes payable | (132) |  |  | — |
Proceeds from warrants exercised | 78 |  |  | — |
Net cash provided by financing activities | 1,544 |  |  | 600 |
Effect of changes in exchange rate on cash and cash equivalents | 3,633 |  |  | — |
INCREASE IN CASH AND CASH EQUIVALENTS | 3,634 |  |  | 56 |
CASH AND CASH EQUIVALENTS, beginning of period | 7,177 |  |  | 5 |
CASH AND CASH EQUIVALENTS, end of period | $ | 10,811 |  |  | $ | 61 |
Supplemental cash flow disclosures: |  |  |
Interest paid | $ | 394 |  |  | $ | — |
Noncash financing and investing activities: |  |  |
Common stock issued for consulting services | $ | 94 |  |  | $ | — |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6

Table of Contents
ALT5 SIGMA CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(UNAUDITED)
(Dollars in thousands)

| Series A-1 Preferred |  | Series S-1 Preferred |  | Series B Preferred |  | Series I Preferred |  | Series M Preferred |  | Series Q Preferred |  | Series V Preferred |  | Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Accumulated Other Comprehensive Deficit |  | Noncontrolling Interest |  | Total Stockholders' Equity
| Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |
Balance, December 28, 2024 | 23,480 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 34,207 |  | $ | 8,552 |  |  | 17,000 |  | $ | — |  |  | 3,200 |  | $ | — |  |  | 925,212 |  | $ | 1,321 |  |  | 5,000 |  | $ | — |  |  | 15,417,693 |  | $ | 9 |  |  | $ | 62,207 |  |  | $ | (56,879) |  |  | $ | (2,317) |  |  | $ | 3,925 |  |  | $ | 24,811 |
Common stock issued for warrants exercised | — |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 45,455 |  | — |  |  | 78 |  |  | — |  |  | — |  |  | — |  |  | 78 |
Common stock issued for Series V Preferred converted | — |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | (5,000) |  | — |  |  | 600,000 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Common stock issued for consulting agreement | — |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 15,499 |  | — |  |  | 94 |  |  | — |  |  | — |  |  | — |  |  | 94 |
Foreign currency adjustment | — |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  | — |  |  | — |  |  | — |  |  | 3,633 |  |  | — |  |  | 3,633 |
Net loss | — |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  | — |  |  | — |  |  | (2,861) |  |  | — |  |  | (425) |  |  | (3,286) |
Balance, March 29, 2025 | 23,480 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 34,207 |  | $ | 8,552 |  |  | 17,000 |  | $ | — |  |  | 3,200 |  | $ | — |  |  | 925,212 |  | $ | 1,321 |  |  | — |  | $ | — |  |  | 16,078,647 |  | $ | 9 |  |  | $ | 62,379 |  |  | $ | (59,740) |  |  | $ | 1,316 |  |  | $ | 3,500 |  |  | $ | 25,330 |

| Series A-1 Preferred |  | Series S-1 Preferred |  | Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Total Stockholders' Equity
| Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |
Balance, December 30, 2023 | 193,730 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 4,957,647 |  | $ | 3 |  |  | $ | 47,323 |  |  | $ | (50,634) |  |  | $ | (3,308) |
Share based compensation | — |  | — |  |  | — |  | — |  | — |  | — |  |  | 345 |  |  | — |  |  | 345 |
Reclassification of Series S stock to liability | — |  | — |  |  | — |  | — |  | — |  | — |  |  | (339) |  |  | — |  |  | (339) |
Reclassification of Series S stock to permanent equity | — |  | — |  |  | — |  | — |  | — |  | — |  |  | — |  |  | — |  |  | 7,993 |
Common stock issued for equity financing | — |  | — |  |  | — |  | — |  | 884,880 |  | 1 |  |  | 626 |  |  | — |  |  | 627 |
Common stock issued for consulting agreement | — |  | — |  |  | — |  | — |  | 200,000 |  | — |  |  | 232 |  |  | — |  |  | 232 |
Common stock issued in lieu of note payable obligations | — |  | — |  |  | — |  | — |  | 600,000 |  | 1 |  |  | 366 |  |  | — |  |  | 367 |
Common stock issued for RSU's granted | — |  | — |  |  | — |  | — |  | 908,852 |  | — |  |  | — |  |  | — |  |  | — |
Net income | — |  | — |  |  | — |  | — |  | — |  | — |  |  | — |  |  | (2,144) |  |  | (2,144) |
Balance, March 30, 2024 | 193,730 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 7,551,379 |  | $ | 5 |  |  | $ | 48,553 |  |  | $ | (52,778) |  |  | $ | 3,773 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Table of Contents
Note 1: Background
The accompanying consolidated financial statements include the accounts of ALT5 Sigma Corporation, a Nevada corporation, and its subsidiaries (collectively, the “Company” or “ALT5”). Effective July 15, 2024, the Company changed its corporate name from “JanOne Inc.” to “ALT5 Sigma Corporation,” and also changed its Nasdaq common stock ticker symbol from “JAN” to “ALTS”. The corporate name change was effected through a parent/subsidiary short-form merger of ALT5 Sigma Corporation, the Company’s wholly-owned Nevada subsidiary formed solely for the purpose of effectuating the name change), whereby it merged with and into the Company, with the Company being the surviving entity, albeit with its new name.
The Company had three operating segments – Fintech, Biotechnology, and Corporate and Other.
Fintech
On May 15, 2024, the Company acquired ALT5 Sigma, Inc. (“ALT5 Subsidiary”). ALT5 Subsidiary is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets (see Note 3).
Biotechnology
During September 2019, ALT5 Sigma Corporation, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone, (“JAN123”). The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales. In that regard, we have previously announced our intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary. The short-term intended result of that series of transactions would be for us to own a controlling interest in that subsidiary, but to decouple it from us so that it would operate on a stand-alone basis.
Corporate and Other
Our Corporate and Other segment consists of certain corporate general and administrative costs.
The Company reports on a 52- or 53-week fiscal year. The Company’s 2024 fiscal year (“2024”) ended on December 28, 2024, and the current fiscal year (“2025”) will end on December 27, 2025.
Going concern
The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company’s ability to do so.
The Company currently faces a challenging competitive environment and is focused on improving its overall profitability and liquidity, which includes managing expenses. The Company reported a net loss of approximately $2.9 million for the 13 weeks ended March 29, 2025. Additionally, as of March 29, 2025, the Company has total current assets of approximately $31.8 million and total current liabilities of approximately $38.2 million resulting in a net negative working capital of approximately $6.4 million. Cash used in operations was approximately $1.5 million.
8

Table of Contents
The Company intends to raise funds to support future development of JAN 123 and JAN 101 and through a combination of cash flows derived from its acquisition of ALT5 (see Note 3), capital raises, and/or structured arrangements. However, the success of such funding cannot be assured. The Company currently expects that the biotechnology subsidiary transaction discussed above will allow us to finance our Phase III clinical trial for JAN123. No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders or our ownership interest in the to-be-effectuated biotechnology subsidiary. The short-term intended result of that transaction would be for us to own a controlling interest in that subsidiary, but to decouple it from us so that it would operate on a stand-alone basis.
Note 2: Summary of Significant Accounting Policies
B asis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 28, 2024.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the Soin merger, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.
Financial Instruments
Financial instruments consist primarily of cash, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of trade and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments.
Digital Assets and other Receivables
Digital assets and other receivables are the Company’s digital assets and its customer prepayments in the form of digital assets. The Company holds all digital assets in secure non-custodial wallets through the wallet services from Fireblocks. As of March 29, 2025 and December 28, 2024, the outstanding balance of digital assets and other receivables was approximately $14.5 million and $23.8 million, respectively.
Digital Assets and other Payables
Digital assets and other payables are liabilities that represent the Company’s obligation to deliver the settlement of transactions in the form of digital assets and or cash. The Company safeguards these digital assets and cash for customers and is obligated to safeguard them from loss, theft, or other misuse. The Company recognizes digital assets and other payables, on initial recognition and at each reporting date, at fair value of the digital assets. Any loss, theft, or other misuse would impact the measurement of digital assets and other payables. As of March 29, 2025, the outstanding balance of digital assets and other payables was approximately $25.2 million, of which approximately $14.5 was digital assets and $10.6 was cash deposits. As of December 28, 2024, the outstanding balance of digital assets and other payables was approximately $30.9 million, of which approximately $23.8 million was digital assets and $7.1 million was cash deposits.
9

Table of Contents
Revenue Recognition
Revenue recognition applies to the Company’s Fintech segment only, as the Company’s Biotech segment has not recognized revenue to date. Revenue is recognized under Topic 606 in a manner that reasonably reflects the delivery of its services and products to customers in return for expected consideration and includes the following elements:
1.Executed contracts with the Company’s customers that it believes are legally enforceable;
2.Identification of performance obligations in the respective contract;
3.Determination of the transaction price for each performance obligation in the respective contract;
4.Allocation of the transaction price to each performance obligation; and
5.Recognition of revenue only when the Company satisfies each performance obligation.
These five elements, as applied to each of the Company’s revenue category, is summarized below:
1.Product sales – revenue is recognized at the time of sale of equipment to the customer.
2.Service sales – revenue is recognized based on when the service has been provided to the customer.
The Company’s service is comprised of a single performance obligation to buy and sell or convert digital assets to currencies. That is, the Company is the counter party to all transactions between customers and liquidity providers and presents revenue for the fees earned on a net basis.
The Company is acting as principal in all transactions, and control the digital assets being provided before it is transferred to the buyer, and has risk related to the digital assets, and is responsible for the fulfillment of the digital asset transactions. The Company sets the price for the digital assets by aggregating prices from several liquidity providers and displays them on the Company’s platform. As a result, the Company acts as a price discovery service and acts as a principal facilitating the ability for a customer to purchase or sell digital assets.
The Company considers its performance obligation satisfied, and recognizes revenue, at the point in time the transaction is processed. Contracts with customers are usually open-ended and can be terminated by either party without a termination penalty. Therefore, contracts are defined at the transaction level and do not extend beyond the service already provided.
The Company charges a fee at the transaction level. The transaction price, represented by the trading fee, is calculated based on volume and varies depending on payment type and the value of the transaction. Digital asset purchases or sale transactions executed by a customer on the Company’s platform is based on tiered pricing that is driven primarily by transaction volume processed for a specific historical period. The Company has concluded that this volume-based pricing approach does not constitute a future material right since the discount is within a range typically offered to a class of customers with similar volume. The transaction fee is collected from the customer at the time the transaction is executed. In certain instances, the transaction fee can be collected in digital assets, with revenue measured based on the amount of digital assets received and the fair value of the digital assets at the time of the transaction. The Company also marks up or down the digital asset prices and earns revenue from the spread between the buying and selling price. The Company also earns a fee from transfers of currencies and or digital assets. The transfer fees are nominal and are set to offset the fees associated with banking and or blockchain mining fees.
Stock-Based Compensation
The Company from time to time grants stock options to employees, non-employees and Company executives and directors. Such awards are valued based on the grant date fair-value of the instruments. The value of each award is amortized on a straight-line basis over the vesting period.
Recently Issued Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted.
10

Table of Contents
The Company does not anticipate this guidance will have a material impact upon its financial position and results of operations.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.
Note 3: Mergers and Acquisitions
Qoden
On November 8, 2024, the Company acquired the Qodex Cryptocurrency Exchange Software platform and other related assets from Qoden Technologies, LLC, a provider of technology solutions for the blockchain industry. The purchase price was $2.2 million, consisting of $2.0 million, or 771,010 shares, of the Company’s Series Q Convertible Preferred Stock and $0.2 million in cash. The Series Q Convertible Stock was valued at $2.594 per share on the date issued, and is subject to a mandatory eight-calendar-quarter leak-out, such that no more than twelve-and-one-half percent of the shares may be converted into shares of the Company’s common stock on a trailing quarterly basis over a period of two years, and are subject to vesting provisions. The $0.2 million in cash is payable in increments of $10,000 per month for 24 months, commencing on the first day of the month following closing. The acquisition was determined to be an asset acquisition for accounting purposes.
ALT5
On May 14, 2024, the Company acquired its ALT5 Subsidiary, which is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. ALT5 Subsidiary, through its respective subsidiaries, offers two main platforms to its customers: “ALT5 Pay” and “ALT5 Prime.” ALT5 Pay is a crypto-currency payment gateway that enables registered and approved global merchants to accept and make crypto-currency payments or to integrate the ALT5 Pay payment platform into their application or operations using the plugin with WooCommerce and or ALT5 Pay’s checkout widgets and APIs. Merchants have the option to convert to fiat currency (US Dollars, Canadian Dollars, Euros, and British Pounds Sterling) automatically or to receive their payment in digital assets.
As consideration under the acquisition, the Company issued 1,799,100 shares of its common stock to the legacy equity holders of the capital stock of ALT5 Subsidiary. Those shares represented approximately 19.9% of the Company's then-issued and outstanding shares of common stock. Each of the shares of the Company's newly-issued common stock was valued at $4.14, which was the Nasdaq Historical NOCP on Thursday, May 9, 2024, the day immediately prior to the date on which the agreement was executed. The Company also issued 34,207 shares of its newly-designated Series B Preferred Stock (the “Series B Stock”) to the legacy equity holders of the capital stock of ALT5. In connection with the closing of the acquisition of ALT5 Subsidiary, the Company also issued 3,200 shares of its newly-designated Series M Preferred Stock (the “Series M Stock”) to two entities that acted as finders for the transaction.
The fair value of the purchase price components outlined above was $16.0 million due to fair value adjustments for the shares of Series B Stock and Series M Stock, as detailed below (in $000’s):

Common stock |  | $ | 7,448 |
Series B preferred stock |  | 8,552 |
Total purchase price |  | $ | 16,000 |

Under the preliminary purchase price allocation, the Company recognized goodwill of approximately $11.7 million, which is calculated as the excess of both the consideration exchanged and liabilities assumed as compared to the fair value of the identifiable assets acquired. The values assigned to the assets acquired and liabilities assumed are based on their estimates of fair value available as of May 10, 2024, as calculated by an independent third-party firm. Because the transaction was considered a stock purchase for tax purposes, none of the goodwill arising from the acquisition will be deductible for tax purposes. During the year ended December 28, 2024, the Company recorded a noncash fair value adjustment related to deferred tax liabilities and other liabilities acquired in the aggregate amount of approximately $7.9 million, which was
11

Table of Contents
recorded to goodwill. The table below outlines the purchase price allocation of the purchase for ALT5 Subsidiary to the acquired identifiable assets, liabilities assumed and goodwill (in $000’s):

Total purchase price |  |  | $ | 16,000 |
Accounts payable |  |  | 267 |
Accrued liabilities |  |  | 7,866 |
Digital assets payable |  |  | 16,763 |
Debt |  |  | 7,613 |
Total liabilities assumed |  |  | 32,509 |
Total consideration |  |  | 48,509 |
Cash |  |  | 5,853 |
Accounts receivable |  |  | 2,917 |
Digital assets receivable |  |  | 9,082 |
Intangible assets |  |  |
Customer relationships |  | $ | 13,925 |  |
Trade names |  | 2,675 |  |
Developed technology |  | 1,850 |  |
Subtotal intangible assets |  |  | 18,450 |
Other |  |  | 493 |
Total assets acquired |  |  | 36,795 |
Total goodwill |  |  | $ | 11,714 |

Note 4: Trade and other receivables
The Company’s trade and other receivables as of March 29, 2025 and December 28, 2024, respectively, were as follows (in $000’s):

| March 29, 2025 |  | December 28, 2024
Other receivables | $ | 5,166 |  |  | $ | 2,530 |
Trade and other receivables, net | $ | 5,166 |  | 331000 | $ | 2,530 |

Note 5: Prepaids and other current assets
Prepaids and other current assets as of March 29, 2025 and December 28, 2024 consist of the following (in $000’s):

| March 29, 2025 |  | December 28, 2024
Prepaid other | $ | 1,273 |  |  | $ | 1,518 |
Total prepaid expenses and other current assets | $ | 1,273 |  |  | $ | 1,518 |

Note 6: Property and Equipment
Property and equipment as of March 29, 2025 and December 28, 2024 consist of the following (in $000’s):

|  | March 29, 2025 |  | December 28, 2024
Projects under construction |  | $ | 1,170 |  |  | $ | 1,170 |
Total property and equipment, net |  | $ | 1,170 |  |  | $ | 1,170 |

12

Table of Contents
Note 7: Leases
In connection with its acquisition of ALT5 Subsidiary (see Note 3), the Company leases commercial office space. These assets and properties are leased under noncancelable agreements that expire at various future dates. The agreements, which have been classified as operating leases, provide for minimum rent and require the Company to pay all insurance, taxes, and other maintenance costs. As a result, the Company recognizes assets and liabilities for leases with lease terms greater than 12 months. The amounts recognized reflect the present value of remaining lease payments for all leases. The discount rate used is an estimate of the Company’s blended incremental borrowing rate based on information available associated with each subsidiary’s debt outstanding at lease commencement. In considering the lease asset value, the Company considers fixed and variable payment terms, prepayments and options to extend, terminate or purchase. Renewal, termination, or purchase options affect the lease term used for determining lease asset value only if the option is reasonably certain to be exercised.
The following table details the Company’s right of use assets and lease liabilities as of March 29, 2025 and December 28, 2024 (in $000’s):

| March 29, 2025 |  | December 28, 2024
Right of use asset - operating leases | $ | 116 |  |  | $ | 121 |
Lease liabilities: |  |  |
Current - operating | 18 |  |  | 10 |
Long term - operating | 107 |  |  | 113 |

As of March 29, 2025, the weighted average remaining lease term for operating leases is 4.67 years. The Company’s weighted average discount rate for operating leases is 12.8%. Total cash payments for operating leases for the 13 weeks ended March 29, 2025 was approximately $2,700. No cash payments for operating leases were made during the 13 weeks ended March 30, 2024. Additionally, the Company recognized approximately no right of use assets or lease liabilities during the 13 weeks ended March 29, 2025.
Total present value of future lease payments of operating leases as of March 29, 2025 (in $000’s):

Twelve months ended |
2026 | $ | 33 |
2027 | 35 |
2028 | 36 |
2029 | 38 |
2030 | 26 |
Total | 168 |
Less implied interest | (43) |
Present value of payments | $ | 125 |

13

Table of Contents
Note 8: Intangible Assets
Intangible assets as of March 29, 2025 and December 28, 2024 consist of the following (in $000’s):

| March 29, 2025 |  | December 28, 2024
Soin intangibles | $ | 19,293 |  |  | $ | 19,293 |
Qoden intangible | 1,536 |  |  | 1,536 |
Patents and domains | 4 |  |  | 4 |
Trade names | 2,675 |  |  | 2,675 |
Customer relationships | 13,925 |  |  | 13,925 |
Developed technology | 1,850 |  |  | 1,850 |
Intangible assets | 39,283 |  |  | 39,283 |
Less accumulated amortization | (6,063) |  |  | (4,853) |
Total intangible assets | $ | 33,220 |  |  | $ | 34,430 |

Intangible amortization expense was $1.2 million and $639,000 for the 13 weeks ended March 29, 2025 and March 30, 2024, respectively.
Qoden Intangible Assets
On November 8, 2024, the Company acquired the Qodex Cryptocurrency Exchange Software platform and other related assets from Qoden Technologies, LLC, a provider of technology solutions for the blockchain industry. The Company will amortize the intangible assets over a two-year period (see Note 3).
ALT5 Subsidiary Intangible Assets
On May 14, 2024, the Company acquired its ALT5 Subsidiary, which is a fintech company that provides next generation blockchain-powered technologies to enable a migration to a new global financial paradigm. As part of the acquisition, the Company acquired trade names, customer relationships, and developed technology, which will be amortized over a period of seven years, 10 years, and five years, respectively (see Note 3).
Soin Intangible Assets
Effective as of December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone. The assets acquired by the Company consist of 1) three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain, 2) final formula for Naltrexone, and 3) orphan drug designation as approved by the FDA. The Company reviewed the assets acquired and determined that no in-process research and development costs were acquired as part of the transaction, and, thus, all assets acquired represent intellectual property and should be capitalized. The Company will amortize the intangible assets ratably over a 10-year period.
Note 9: Accrued Liabilities
Accrued liabilities as of March 29, 2025 and December 28, 2024 consist of the following (in $000’s):

| March 29, 2025 |  | December 28, 2024
Compensation and benefits | $ | 222 |  |  | $ | 204 |
Accrued guarantees | 309 |  |  | 309 |
Accrued taxes | 695 |  |  | 362 |
Accrued interest | 764 |  |  | 789 |
Accrued Qoden payments | 114 |  |  | 109 |
Accrued litigation/legal | 50 |  |  | 50 |
Other | 706 |  |  | 730 |
Total accrued expenses | $ | 2,860 |  |  | $ | 2,553 |

14

Table of Contents
Note 10: Debentures
Debentures outstanding as of March 29, 2025 and December 28, 2024 consisted for the following (in $000’s):

| March 29, 2025 |  | December 28, 2024
Interest rate of 12%, maturity date of June 30, 2025 | $ | 563 |  |  | $ | 563 |
Total debentures | $ | 563 |  |  | $ | 563 |

ALT5 Subsidiary issued seven debentures over a period from October 2018 through September 2019. The debentures bear interest at 12% per annum and mature as of June 30, 2025.
Note 11: Debt
Long-term debt as of March 29, 2025 and December 28, 2024 consisted of the following (in $000’s):

| March 29, 2025 |  | December 28, 2024
Legacy subsidiary fixed deposits | $ | 5,503 |  |  | $ | 4,247 |
Legacy subsidiary loan | 3,334 |  |  | 3,782 |
Unaffiliated third-party | 3,916 |  |  | 3,508 |
Other | — |  |  | 33 |
Total notes payable, related parties | 12,753 |  |  | 11,570 |
Less current portion | (3,334) |  |  | — |
Total long-term notes payable, related parties | $ | 9,419 |  |  | $ | 11,570 |

Legacy Subsidiary Fixed Deposits
ALT5 Subsidiary entered into several Corporate Fixed Deposit Agreements with otherwise unaffiliated third-parties, pursuant to which the Company became obligated for an aggregate of $5.5 million, as set forth in the respective agreements. Each obligation bears interest at a rate of 13% or 15% per annum, and has a maturity date range of April 2026 to March 2027. Several of these unaffiliated third-parties agreed to convert their respective investments into Future Equity Agreements for shares of the Company’s subsidiary, Alyea Therapeutic and, consequently, approximately $125,000 of these deposits were reclassified as non-controlling interest. As of March 29, 2025 and December 28, 2024, the outstanding aggregate obligations totaled approximately $5.5 million and $4.2 million, respectively.
Legacy Subsidiary Loan
On August 10, 2023, ALT5 Subsidiary entered into an extension agreement for a Bitcoin promissory note with an otherwise unaffiliated third-party. The Bitcoin promissory note is denominated in Bitcoin and, thus, is adjusted to its fair value each period. Pursuant to the terms of an extension agreement, the maturity date is August 2025. The promissory note bears interest at 15% per annum. As of March 29, 2025 and December 28, 2024, the outstanding balance of the note was approximately $3.3 million and $3.8 million, respectively.
Unaffiliated Third-Party Loans
ICG Note
On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of Isaac Capital Group LLC (“ICG”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6, 2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal amount of the ICG Note on the date of acquisition was approximately $1.2 million. During the year ended December 28, 2024, the third party converted $548,900 of the Company’s obligations under the ICG Note into 900,000 shares of the Company’s common stock. As of March 29, 2025
15

Table of Contents
and December 28, 2024, the amount outstanding on the ICG Note was approximately $0.70 million and $0.7 million, respectively.
Live Note
On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “Live Note”) in favor of Live Ventures Incorporated (“Live”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its final approvals of the amendments on February 7, 2024. On March 6, 2024, Live entered into a Note Purchase Agreement with another otherwise unaffiliated third party, under which the third party acquired the Live Note. The terms and conditions of the acquired Live Note were not modified in connection with its acquisition by the third party. The principal amount of the Live Note on the date of acquisition was approximately $1.0 million. During the year ended December 28, 2024, the third party converted $243,900 of the Company’s obligations under the Live Note into 400,000 shares of the Company’s common stock. As of March 29, 2025 and December 28, 2024, the amount outstanding on the Live Note was approximately $0.80 million and $0.8 million.
Big/Small Debentures
On August 20, 2024, the Company entered into three Purchase Agreements with three otherwise unaffiliated third-party investors (the “Investors”), pursuant to which (1) one Investor agreed to purchase a unit (the “Unit”), consisting of (i) a non-convertible debenture in the principal amount of up to approximately $1.8 million (the “Big Debenture”), and (ii) a warrant (the “Big Warrant”) for the purchase of up to 400,000 shares of the Company’s Common Stock and (2) the two other Investors each agreed to purchase a Unit, consisting of (i) a non-convertible debenture in the principal amount of up to $404,454 (the “Small Debenture”, and, together with the Big Debenture, the “Debentures”) and (ii) a warrant (the “Small Warrant”, and, together with the Big Warrant, the “Warrants”) for the purchase of up 90,909 shares of Common Stock.
The Debentures are unsecured and subordinated to any existing or future debt. The Debentures bear interest at a rate of (i) 1% per month from and after August 20, 2024 (“Original Issue Date”) through and including October 31, 2024, (ii) 3% per month from and after November 1, 2024 through and including January 29, 2025, and (iii) 4% per month from and after January 30, 2025 through and including the date of repayment.
The Big Debenture was issued with an original issue discount (an “OID”) initially of $171,000, which OID can be expanded with up to two potential additions, the first in the amount of $171,000 and, thereafter, in the amount of $342,000, which OIDs will increase the principal amount owing on the Big Debenture. With the original OID, the initial principal amount owing under the Big Debenture is approximately $1.3 million; if, expanded, the principal amount would increase to approximately $1.4 million and, thereafter, potentially to approximately $1.8 million. The first potential increase in the Big Debenture OID would occur if the initial principal amount and interest accrued thereon is not paid in full on or before October 31, 2024. The second potential increase in the OID would occur if the initial principal amount (including the first potential increase in the OID) and interest accrued thereon is not paid in full on or before January 29, 2025.
The Small Debentures were issued with an OID initially of $38,863, which OID can be expanded with up to two potential additions, the first in the amount of $38,863 and, thereafter, in the amount of $77,728, which OIDs will increase the principal amount owing on the Small Debentures. With the original OID, the initial principal amount owing under a Small Debenture is $288,864; if, expanded, the principal amount would increase to $327,726 and, thereafter, potentially to $404,454. The first potential increase in the Small Debenture OID would occur if the initial principal amount and interest accrued thereon is not paid in full on or before October 31, 2024. The second potential increase in the OID would occur if the initial principal amount (including the first potential increase in the OID) and interest accrued thereon is not paid in full on or before January 29, 2025.
As of November 1, 2024, the first of the two additional OIDs was effective. The final maturity date for each of the Debentures is April 28, 2025.
The Big Warrant is exercisable, at an exercise price of $1.71 per share, as follows: (i) 100,000 shares of Common Stock as of Original Issue Date, (ii) contingently for an additional 100,000 shares of Common Stock as of October 31, 2024, if, as of such date, the Company has not repaid in full its obligations under the Big Debenture, and (iii) contingently for an additional 200,000 shares of Common Stock as of January 29, 2025, if, as of such date, the Company has not repaid in full its obligations under the Big Debenture.
16

Table of Contents
The Small Warrant is exercisable, at an exercise price of $1.71 per share, as follows: (i) 22,727 shares of Common Stock as of Original Issue Date, (ii) contingently for an additional 22,727 shares of Common Stock as of October 31, 2024, if, as of such date, the Company has not repaid in full its obligations under the Small Debenture, and (iii) 45,455 shares of Common Stock as of January 29, 2025, if, as of such date, the Company has not repaid in full its obligations under the Small Debenture.
As of November 1, 2024, the contingent second tranche of the Warrants vested.
Each Investor is required to exercise the initial tranche of each Warrant within 15 days of the Original Issue Date. Upon the vesting of each contingent tranche of a Warrant vest, each Investor shall exercise such vested, contingent tranche within 15 days of the vesting of such contingent tranche. If the Company consummates any equity or debt financing before satisfying in full its obligations under the Debentures, then 50% of every net dollar received by the Company from any such financing transaction shall be paid by the Company to the holders of the Debentures, on a pro rata basis, as a mandatory pre-payment thereof. In the event the Company has repaid all sums owing under a Debenture to the Investor, except for an amount equal to any non-conditional OID, the Company has the right, not the obligation, to exercise the vested portion of the Warrant held by the Debenture holder through a set-off of any or all such unpaid OID, on a dollar-for-dollar basis. The Warrants also feature a “cashless” exercise provision. In lieu of making the cash payment otherwise contemplated to be made to the Company upon exercise of a Warrant in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of Common Stock determined according to a formula set forth in the Warrant.
During the quarter ended March 29, 2025, one of the two non-affiliated Investors exercised the remainder of the Small Warrant for a total of 45,455 shares (see Note 14). During the fourth quarter of the year ended December 28, 2024, the non-affiliated Investor exercised the Big Warrant for a total of 200,000 shares of the Company’s common stock, and the other two non-affiliated Investors exercised the Small Warrant for a total of 90,908 shares. Additionally, during the fourth quarter of the year ended December 28, 2024, these unaffiliated third-parties agreed to convert a portion their respective investment into Future Equity Agreements of the Company’s subsidiary, Alyea Therapeutics and, consequently, approximately $1.3 million was reclassified as non-controlling interest. During the 13 weeks ended March 29, 2025, the Company paid approximately $0.2 million, in principal and accrued interest, to one of the two non-affiliated Investors in settlement of its debt. As of March 29, 2025 and December 28, 2024, the outstanding balance due on the debentures was approximately $0.3 million and $0.5 million, respectively, consisting of principal and accrued interest.
Corporate Fixed Deposit Agreement
On September 19, 2024, ALT5 Subsidiary and an investor entered into a 12-month Corporate Fixed Deposit Agreement, pursuant to which ALT5 Subsidiary borrowed $1.5 million at an interest rate of 12% per annum, payable monthly, calculated on the then-unpaid principal amount. Upon maturity, ALT5 Subsidiary is obligated to repay the principal amount in full and any accrued and unpaid interest. The principal may be repaid in full, but not in part, with a pre-payment penalty equivalent to three month’s of interest. As of March 29, 2025 and December 28, 2024, the outstanding balance was approximately $1.6 million and $1.5 million, respectively, consisting of principal and accrued interest.
Personal Fixed Deposit Agreement
On February 1, 2025, ALT5 Subsidiary and an investor entered into a 24-month Personal Fixed Deposit Agreement, pursuant to which ALT5 Subsidiary borrowed $0.5 million at an interest rate of 13% per annum, payable monthly, calculated on the then-unpaid principal amount. Upon maturity, ALT5 Subsidiary is obligated to repay the principal amount in full and any accrued and unpaid interest. The principal may be repaid in full, but not in part, with a pre-payment penalty equivalent to three month’s of interest. As of March 29, 2025, the outstanding balance was approximately $0.5 million.
17

Table of Contents
Note 12: Related Party Debt
Long-term debt payable to related parties as of March 29, 2025 and December 28, 2024 consisted of the following (in $000’s):

| March 29, 2025 |  | December 28, 2024
Isaac Capital Group, 10.0% interest rate, matures December 31, 2024 | $ | 334 |  |  | $ | 327 |
Live Ventures Incorporated, 10.0% interest rate, matures December 31, 2024 | 334 |  |  | 327 |
Isaac Capital Group short-term demand advance | 49 |  |  | 48 |
Novalk Apps SAA, LLP short-term demand advance | 110 |  |  | 110 |
Total notes payable, related parties | 827 |  |  | 812 |
Less current portion | (827) |  |  | (812) |
Total long-term notes payable, related parties | $ | — |  |  | $ | — |

Total future maturities of long-term debt to related parties is as follows (in $000’s):

Twelve months ending March 29, |
2026 | $ | 827 |
Total future maturities of long-term debt, related parties | $ | 827 |

Isaac Capital Group LLC
On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of ICG to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6, 2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal amount of the ICG Note on the date of acquisition was approximately $1.2 million. As of March 29, 2025, the third party converted $183,000 of the Company’s obligation under the ICG Note into 300,000 shares of the Company’s common stock. As of March 29, 2025 and December 28, 2024, the amount outstanding on the ICG Note was approximately $0.3 million (see Note 19).
On April 18, 2024, ICG made a short-term demand advance to the Company in the amount of $0.1 million. The advance bears interest at a rate of 10% per annum until repaid. As of March 29, 2025 and December 28, 2024, the principal amount outstanding was $49,000 and $48,000, respectively (see Note 19).
Live Ventures Incorporated
On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “Live Note”) in favor of Live Ventures to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its final approvals of the amendments on February 7, 2024. On March 6, 2024, Live Ventures entered into a Note Purchase Agreement with another otherwise unaffiliated third party, under which the third party acquired the Live Note. The terms and conditions of the acquired Live Note were not modified in connection with its acquisition by the third party. The principal amount of the Live Note on the date of acquisition was approximately $1.0 million. As of March 29, 2025, the third party converted $183,000 of the Company’s obligation under the Live Note into 300,000 shares of the Company’s common stock. As of March 29, 2025 and December 28, 2024, the amount outstanding on the Live Note was approximately $0.3 million (see Note 19).
Novalk Apps SAA, LLP
On May 28, 2024 and June 3, 2024, Novalk Apps SAA, LLP (“Novalk”) made short-term demand advances in the amount of $120,000 and $100,000, respectively, to the Company. The advances bears interest at a rate of 10% per annum until repaid. As of March 29, 2025 and December 28, 2024, the principal amount outstanding was approximately $0.1 million (see Note 19).
18

Table of Contents
Note 13: Commitments and Contingencies
Litigation
SEC Complaint
On August 2, 2021, the U.S. Securities and Exchange Commission (“SEC”) filed a civil complaint (the “SEC Complaint”) in the United States District Court for the District of Nevada naming the Company and one of its executive officers, Virland Johnson, the Company's Chief Financial Officer, as defendants (collectively, the “Defendants”). Pursuant to an agreed-upon Order of the Court, on May 28, 2024, the Company settled its litigation with the SEC. The Settlement Agreement provided, in pertinent part: “Without admitting or denying the allegations of the complaint (except as provided herein in paragraph 12 and except as to personal and subject matter jurisdiction, which [the Company] admits), [the Company] hereby consents to the entry of the final Judgment in the form attached hereto (the “Final Judgment”) and incorporated by reference herein, which, among other things: “(a) permanently restrains and enjoins [the Company] from violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder [15 U.S.C. § 78j(b) and 17 C.F.R. §§ 240.10b-5]; and (c)[sic] orders [the Company] to pay a civil penalty in the amount of $250,000 under Section 21(d)(3) of the Exchange Act [15 U.S.C. § 78u(d)(3)).” The SEC has agreed to accept four quarterly payments from the Company, each in the amount of $62,500. The Settlement Agreement is attached to the Order as Exhibit 1, both of which documents may be viewed at https://ecf.nvd.uscourts.gov/doc1/115110470966.
The SEC Complaint's remaining allegations relate to financial, disclosure and reporting violations against the executive officer under Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5. The SEC Complaint also alleges various claims against the executive officer under Sections 13(a), 13(b)(2)(A), 13(b)(2)(B) and 13(b)(5) of the Exchange Act and Rules 12b-20, 13a-1, 13a-13, 13a-14, 13b2-1, and 13b2-2. The SEC continues to seek a permanent injunction, civil penalties, and an officer-and-director bar against the executive officer. The foregoing is only a general summary of the SEC Complaint, which may be accessed on the SEC’s website at https://www.sec.gov/litigation/litreleases/2021/lr25155.htm.
Sieggreen
In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, regarding which, as of the date of these financial statements, the Court has not ruled. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims.
Main/270
The Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division, styled, Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant, Case no.: 2:22-cv-01938-ALM-EPD. The Company was a guarantor of the lease between the Plaintiff and ApplianceSmart, Inc. Plaintiff alleged a cause of action against the Company in respect of the guaranty and seeks approximately $90,000 therefor. Plaintiff also seeks approximately $1,420,000 against ApplianceSmart and the Company on a joint and several basis. The Company does not believe that it is obligated to Plaintiff in that amount and the parties continue to negotiate a potential settlement.
Other Commitments
On December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures, a related party. In connection with that sale, as of January 1, 2022, the Company accrued an aggregate amount of future real property lease payments of approximately $767,000 which represented amounts guaranteed or which may have been owed under certain lease agreements to three third party landlords in which the Company either remained the counterparty, was a guarantor, or had agreed to remain contractually liable under the lease (“ApplianceSmart Leases”). A final decree was issued by the court on February 28, 2022, upon the full satisfaction of the Plan, at which time ApplianceSmart emerged from Chapter 11. During the year ended December 28, 2024, the Company reversed approximately $637,000 of the accrual, as the Company is no longer liable for two of these guarantees upon ApplianceSmart's emergence from bankruptcy. As of December 28, 2024, a balance of approximately $130,000 remains as an accrued liability due to an
19

Table of Contents
ongoing dispute concerning one of the leases. The Company and Live Ventures have agreed to divide in half between them any ultimate balance owing thereunder and any attorneys’ fees expended in relation thereto.
The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of March 29, 2025.
Note 14: Stockholders’ Equity
Common Stock: Our Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. During the 13 weeks ended March 29, 2025 and March 30, 2024, no shares of common stock were issued in lieu of professional services.
On January 15, 2025, the Company entered into a six-month consulting agreement with a non-affiliated third-party, pursuant to which the third-party will provide a variety of corporate advisory services related to investment banking matters to the Company. In connection with the agreement, on January 15, 2025, the Company issued to the third-party 15,499 shares of its common stock.
On May 4, 2024, the Company entered into an Asset Purchase Agreement for the purchase of specified assets of an unaffiliated third-party. In connection with this transaction, the Company tendered 5,000 shares of the Company's Series V Convertible Preferred Stock. The conversion ratio of the Series V Convertible Preferred Stock is 1:120, meaning every one share of Series V Convertible Preferred Stock, if and when converted into shares of Common Stock shall convert into 120 shares of Common Stock. On March 12, 2025, the unaffiliated third-party exercised all tendered shares of Series V Convertible Preferred Stock into 600,000 shares of the Company’s common stock.
During the first quarter ended March 29, 2025, the Company issued 45,455 shares of its common stock related to the exercise of warrants under the Small Debenture (see Note 11).
As of March 29, 2025, and December 28, 2024, there were 16,078,647 and 15,417,693 shares, respectively, of common stock issued and outstanding.
Equity Offerings: The Company’s 2024 Plan, which was adopted by the Board in November 2024 and approved by the stockholders at the 2024 annual meeting of stockholders, replaces the 2023 Plan, which replaced the 2016 Plan, which replaced the 2011 Plan. Under the 2024 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is 2,800,000 shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 13 weeks ended March 29, 2025, there were no grants under the 2024 Plan.
The Company's 2023 Plan, which was adopted by the Board in August 2023 and approved by the stockholders at the 2023 Annual Meeting of Stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (2,000,000) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 13 weeks ended March 29, 2025 and March 30, 2024, the Company recognized $0 and $345,000 in share-based compensation expense related to the 908,852 RSU's that were awarded and immediately vested.
The Company's 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of March 29, 2025 and December 28, 2024, 100,000 options were outstanding under the 2016 Plan.
The Company's 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of March 29, 2025 and December 28, 2024, 8,000 were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan.
20

Table of Contents
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. There were no stock options granted during the 13 weeks ended March 29, 2025.
Additional information relating to all outstanding stock options is as follows:

| Options Outstanding |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value |  | Weighted Average Remaining Contractual Life
Outstanding at December 28, 2024 | 108,000 |  | $ | 5.03 |  |  | $ | 68 |  |  | 5.5
Outstanding at March 29, 2025 | 108,000 |  | $ | 5.03 |  |  | $ | 68 |  |  | 5.2
Exercisable at March 29, 2025 | 60,000 |  | $ | 3.32 |  |  | $ | 68 |  |  | 5.6

The Company recognized no share-based compensation expense related to stock options for the 13 weeks ended March 29, 2025 and March 30, 2024.
As of March 29, 2025, the Company has the Company had no unrecognized share-based compensation expense associated with equity awards.
Series A-1 Convertible Preferred Stock
Shares of Series A-1 Preferred Stock are convertible into the Company’s common shares at a ratio of 20:1. No shares were converted during the 13 weeks ended March 29, 2025. As of March 29, 2025 and December 28, 2024, there were 23,480 shares of Series A-1 Convertible Preferred Stock outstanding.
Series I Convertible Preferred Stock
Shares of Series I Preferred Stock are convertible into the Company’s common shares at a ratio of 100:1. No shares were converted during the 13 weeks ended March 29, 2025. As of March 29, 2025 and December 28, 2024, there were 17,000 shares of Series I Convertible Preferred Stock outstanding.
Series Q Convertible Preferred Stock
Shares of Series Q Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. No shares were converted during the 13 weeks ended March 29, 2025. As of March 29, 2025 and December 28, 2024, there were 925,212 shares of Series Q Convertible Preferred Stock outstanding.
Series S Preferred Stock
On December 28, 2022 the Company acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company's Series S Convertible Preferred Stock. Shares of Series S Convertible Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. No shares were converted during the 13 weeks ended March 29, 2025. As of March 29, 2025 and December 28, 2024, there were 100,000 shares of Series S Convertible Preferred Stock outstanding.
Series V Convertible Preferred Stock
Shares of Series V Preferred Stock are convertible into the Company’s common shares at a ratio of 120:1. During the 13 weeks ended March 29, 2025, all outstanding shares of Series V Preferred Stock were converted into 600,000 shares of the Company’s common stock (see above). As of March 29, 2025 and December 28, 2024, there were 0 and 5,000 shares of Series V Convertible Preferred Stock outstanding, respectively.
Note 15: Mezzanine Equity
During the year ended December 28, 2024, the Company reclassified approximately $2.7 million from mezzanine equity to current liabilities, and approximately $8.0 million from mezzanine equity to permanent equity. As of March 29, 2025, the outstanding balance in mezzanine equity was approximately $3.9 million.
21

Table of Contents
Note 16: Earnings Per Share
Net income (loss) per share is calculated using the weighted average number of shares of common stock outstanding during the applicable period. Basic weighted average common shares outstanding do not include shares of restricted stock that have not yet vested, although such shares are included as outstanding shares in the Company’s Consolidated Balance Sheet. Diluted net income (loss) per share is computed using the weighted average number of common shares outstanding and if dilutive, potential common shares outstanding during the period. Potential common shares consist of the additional common shares issuable in respect of restricted share awards, stock options and convertible preferred stock.
The following table presents the computation of basic and diluted net income (loss) per share (in $000’s, except share and per–share data):

| For the Thirteen Weeks Ended
| March 29, 2025 |  | March 30, 2024
Basic and diluted |  |  |
Net loss | $ | (2,861) |  |  | $ | (2,144) |
Weighted average common shares outstanding | 15,550,706 |  | 6,308,331
Basic and diluted loss per share | $ | (0.18) |  |  | $ | (0.34) |

Potentially dilutive securities totaling approximately 8.9 million and 3.8 million were excluded from the calculation of diluted earnings per share for the 13 weeks ended March 29, 2025 and March 30, 2024, respectively, because the effects were anti-dilutive.
Note 17: Income Taxes
The Company recorded an income tax provision of approximately $285,000 for the 13 weeks ended March 29, 2025, and an income tax benefit of $75,000 for the 13 weeks ended March 30, 2024. The Company’s overall effective tax rate was -11.1% and 3.4% for the 13 weeks ended March 29, 2025 and March 30, 2024, respectively. The effective tax rates and related provisional tax amounts vary from the U.S. federal statutory rate primarily due to state taxes and certain non-deductible expenses.
Note 18: Segment Information
The Company operates within targeted markets through three reportable segments for continuing operations: Fintech, Biotech, and Corporate and Other.
22

Table of Contents
The following tables present the Company's segment information for the 13 weeks ended March 29, 2025 and March 30, 2024 (in $000's):

| Thirteen Weeks Ended
| March 29, 2025 |  | March 30, 2024
Revenues |  |  |
Fintech | $ | 5,514 |  |  | $ | — |
Biotech | — |  |  | — |
Corporate and other | — |  |  | — |
Total Revenues | $ | 5,514 |  |  | $ | — |
Gross profit |  |  |
Fintech | $ | 2,591 |  |  | $ | — |
Biotech | — |  |  | — |
Corporate and other | — |  |  | — |
Total Gross profit | $ | 2,591 |  |  | $ | — |
Operating loss |  |  |
Fintech | $ | (362) |  |  | $ | — |
Biotech | (540) |  |  | (701) |
Corporate and other | (1,268) |  |  | (1,105) |
Total Operating loss | $ | (2,170) |  |  | $ | (1,806) |
Depreciation and amortization |  |  |
Fintech | $ | 728 |  |  | $ | — |
Biotech | 482 |  |  | 639 |
Corporate and other | — |  |  | — |
Total Depreciation and amortization | $ | 1,210 |  |  | $ | 639 |
Interest expense, net |  |  |
Fintech | $ | 376 |  |  | $ | — |
Biotech | — |  |  | 252 |
Corporate and other | 344 |  |  | — |
Total Interest expense, net | $ | 720 |  |  | $ | 252 |
Net loss before income taxes |  |  |
Fintech | $ | (346) |  |  | $ | — |
Biotech | (540) |  |  | (701) |
Corporate and other | (1,690) |  |  | (1,518) |
Total Net income before income taxes | $ | (2,576) |  |  | $ | (2,219) |

Note 19: Related Parties
Shared Services
Tony Isaac, the Company’s Chief Executive Officer, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures and managing member of Isaac Capital Group LLC (“ICG”). Tony Isaac, Chief Executive Officer, and Richard Butler, Board of Directors member of the Company, are members of the Board of Directors of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $30,000 and $338,000 for the 13 weeks ended March 29, 2025 and March 30, 2024, respectively. Customer Connexx rents approximately 9,900 square feet of office space from Live Ventures in Las Vegas, Nevada.
Notes with Live Ventures and ICG
On February 7, 2024, the Company entered into a promissory notes with each of Live Ventures and ICG. The initial principal amount of each note is $300,000, with an interest rate of 10% per annum. At the Company’s option, the obligation under each note is convertible after the six-month anniversary thereof at a per-share conversion price of $0.61,
23

Table of Contents
subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors approved the issuance of the two notes on February 7, 2024. As of March 29, 2025 and December 28, 2024, the balances outstanding on each of the promissory notes was approximately $0.3 million, consisting of principal and accrued interest (see Note 12).
Short-Term Advances
On April 18, 2024, ICG made a short-term demand advance to the Company in the amount of $0.1 million. The advance bears interest at a rate of 10% per annum until repaid. As of March 29, 2025 and December 28, 2024, the principal amount outstanding was $49,000 and $48,000, respectively (see Note 12).
On May 28, 2024 and June 3, 2024, Novalk made short-term demand advances in the amount of $120,000 and $100,000, respectively, to the Company. Juan Yunis, an employee of Live Ventures, is the managing member of Novalk. The advances bears interest at a rate of 10% per annum until repaid. As of March 29, 2025 and December 28, 2024, the principal amount outstanding was $0.1 million (see Note 12).
Note 20: Subsequent event
The Company has evaluated subsequent events through the filing of this Form 10-Q, and determined that there have been no events that have occurred that would require adjustments to disclosures in its condensed consolidated financial statements other than as discussed below:
Mswipe Transaction
Effective on May 9, 2025, we and our indirect, wholly-owned second tier Canadian subsidiary entered into an agreement to purchase all of the outstanding capital stock of an entity that, through its subsidiaries, offers multi-currency, fiat- and crypto-enabled payment card services. The business trades under the name Mswipe. Through a suite of physical and virtual cards that are available on both the Visa® and Mastercard® networks, the acquired operations enable users seamlessly to spend traditional and digital currencies across the globe. The acquired platform is built with robust compliance frameworks, advanced security protocols, and real-time exchange capabilities, which allow for fast, secure, and borderless transactions. This is a B2B solution, which, when combined with our current solutions, bridges the gap between the crypto economy and traditional financial systems—while ensuring regulatory alignment, interoperability with existing payment networks, and a seamless user experience for institutional partners and their end-users.
The purchase price for this transaction consisted of our (i) issuing one million restricted shares of our common stock to the three sellers, valued at the Historical NOCP on May 9, 2025 of $6.10, (ii) granting five hundred thousand four-year common stock warrants to the three sellers, with a per-share exercise price of $5.50 (which was the approximate market price at the time that we reached an agreement in principal for this transaction), (iii) issuing shares to two of the sellers in “Alyea Therapeutics Corporation,” our biotech business that we are in process of separating from our core business, which shares we valued at $4.8 million, and (iv) issuing two 14-month straight promissory notes in the aggregate initial principal balance of approximately one million dollars with an interest rate at the AFR for quarterly compounded notes of 3.99% per annum and all principal and interest due at the maturity date. We also are acknowledging an equivalent 14-month term straight promissory note at the acquired company level that pre-dated our acquisition. The principal balance as of May 9, 2025 was approximately $5.1 million and the interest was reset to match that of the two notes that we issued. We also granted the sellers the right to one earn-out payment in the amount of $20 million (payable in cash or unregistered shares of our common stock) right if the Operating Subsidiaries generate a minimum of $15 million in annualized or actual total revenue from the assets owned by the Operating subsidiaries at May 9, 2025. Please see Exhibit 10.120 for the specific calculation modalities of the earn-out payments. None of the shares of our common stock, the shares underlying the common stock purchase warrants, and the shares of common stock of Alyea has any registration or equivalent rights.
The foregoing brief summary description of certain terms and provisions of (i) the purchase of the business that trades under the name Mswipe and the related covenant against competition do not purport to be complete and are qualified in their entirety by reference to the full text of the form of Share Purchase Agreement by and among ALT5 Sigma Corporation, ALT 5 Sigma, Inc., and the selling parties and related interest holders signatory thereto, in respect of the “Mswipe transaction”, dated May 9, 2025, and the form of Covenant Against Competition Agreement, a copy of each of which is filed as an exhibit to this Quarterly Report as Exhibit 10.120 and Exhibit 10.121, respectively, (ii) the form of Common Stock Purchase Agreement, granted May 9, 2025 in connection with the Mwsipe transaction, a copy of which is filed as an exhibit to this Quarterly Report as Exhibit 10.122; and (iii) the form of the 14-month Straight Promissory Note issued in connection with the “Mswipe transaction”, dated May 9, 2025, a copy of which is filed as an exhibit to this
24

Table of Contents
Quarterly Report as Exhibit 10.123. Readers are encouraged to read those Exhibits in full for a more comprehensive understanding of the Mswipe transaction.
25

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity and certain other factors that may affect our future results. Dollars stated in thousands, except per–share amounts.
Forward-Looking and Cautionary Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties. You can identify forward-looking statements because they contain words such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘estimates’’ or ‘‘anticipates’’ or similar expressions that concern our strategy, plans or intentions. Any statements we make relating to our future operations, performance and results, and anticipated liquidity are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those we expected. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, including, without limitation, in conjunction with the forward-looking statements included in this Form 10-Q, are disclosed in “Item 1-Business, Item 1A – Risk Factors” of our Form 10-K and Part II, Item 1A of this Form 10-Q.
We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Our MD&A should be read in conjunction with our Form 10-K (including the information presented therein under the caption Risk Factors), together with our Quarterly Reports on Forms 10-Q and other publicly available information. All amounts herein are unaudited.
Our Company
Through our Fintech segment, we provide next generation blockchain-powered technologies to enable a migration to a new global financial paradigm, and, through our Biotechnology segment, we are focused on finding treatments for conditions that cause chronic pain and bringing to market drugs with non-addictive and non-sedative pain-relieving properties.
During the periods disclosed in this Quarterly Report, we operated three reportable segments:
•Fintech: Our Fintech segment provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets
•Biotechnology: Our Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. We have previously announced our intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary. The short-term intended result of that series of transactions would be for to decouple it from us so that it would operate on a stand-alone basis.
•Corporate and Other: Our Corporate and Other segment consists of certain corporate general and administrative costs.
Adjusted EBITDA
We evaluate the performance of our operations based on financial measures such as “Adjusted EBITDA”, which is a non-U.S. GAAP financial measure. We define Adjusted EBITDA as net income (loss) before interest expense, interest income, income taxes, depreciation, amortization, stock-based compensation, and other non-cash or nonrecurring charges. We believe that Adjusted EBITDA is an important indicator of the operational strength and performance of the business, including the business’ ability to fund acquisitions and other capital expenditures, and to service its debt. Additionally, this measure is used by management to evaluate operating results and perform analytical comparisons and identify strategies to improve performance. Adjusted EBITDA is also a measure that is customarily used by financial analysts to evaluate a company's financial performance, subject to certain adjustments. Adjusted EBITDA does not represent cash flows from operations, as defined by U.S. GAAP, and should not be construed as an alternative to net income or loss and is indicative
26

Table of Contents
neither of our results of operations, nor of cash flows available to fund all our cash needs. It is, however, a measurement that the Company believes is useful to investors in analyzing its operating performance. Accordingly, Adjusted EBITDA should be considered in addition to, but not as a substitute for, net income, cash flow provided by operating activities, and other measures of financial performance prepared in accordance with U.S. GAAP. As companies often define non-U.S. GAAP financial measures differently, Adjusted EBITDA, as calculated by the Company, should not be compared to any similarly titled measures reported by other companies.
For the Thirteen Weeks Ended March 29, 2025 and March 30, 2024
Results of Operations
The following table sets forth certain statement of operations items and as a percentage of revenue, for the periods indicated (in $000's):

| 13 Weeks Ended |  | 13 Weeks Ended
| March 29, 2025 |  | March 30, 2024
Statement of Operations Data: |  |  |
Revenues | $ | 5,514 |  |  | $ | — |
Cost of revenues | 2,923 |  |  | — |
Gross profit | 2,591 |  |  | — |
Selling, general and administrative expenses | 4,761 |  |  | 1,806 |
Operating loss | (2,170) |  |  | (1,806) |
Interest expense, net | (720) |  |  | (252) |
Unrealized loss on marketable securities | — |  |  | (190) |
Unrealized gain on exchange transactions | 87 |  |  | — |
Realized gain on exchange transactions | 308 |  |  | — |
Other income, net | (81) |  |  | 29 |
Net loss before provision of income taxes | (2,576) |  |  | (2,219) |
Income tax benefit | 285 |  |  | (75) |
Net loss | $ | (2,861) |  |  | $ | (2,144) |
Adjusted EBITDA (a) |  |  |
Fintech | $ | 1,153 |  |  | $ | — |
Biotech | (58) |  |  | 190 |
Corporate & Other | (1,257) |  |  | (683) |
Total Adjusted EBITDA | $ | (162) |  |  | $ | (493) |
Adjusted EBITDA as a percentage of revenue |  |  |
Fintech | 20.9 | % |  | N/A
Biotech | N/A |  | N/A
Corporate & Other | N/A |  | N/A
Consolidated adjusted EBITDA as a percentage of revenue | (2.9 | %) |  | N/A

(a)See reconciliation of net income to Adjusted EBITDA below.
27

Table of Contents
The following tables set forth revenues for key product and service categories, percentages of total revenue and gross profits earned by key product and service categories and gross profit percent as compared to revenues for each key product category indicated (in $000's):

| 13 Weeks Ended |  | 13 Weeks Ended
| March 29, 2025 |  | March 30, 2024
| Net Revenue |  | Percent of Total |  | Net Revenue |  | Percent of Total
Revenue |  |  |  |  |  |  |
Fintech | $ | 5,514 |  |  | 100.0 | % |  | $ | — |  |  | — | %
Biotech | — |  |  | — | % |  | — |  |  | — | %
Corporate and other | — |  |  | — | % |  | — |  |  | — | %
Total revenue | $ | 5,514 |  |  | 100.0 | % |  | $ | — |  |  | — | %

| 13 Weeks Ended |  | 13 Weeks Ended
| March 29, 2025 |  | March 30, 2024
| Gross Profit |  | Gross Profit Percentage |  | Gross Profit |  | Gross Profit Percentage
Gross Profit |  |  |  |  |  |  |
Fintech | $ | 2,591 |  |  | 47.0 | % |  | $ | — |  |  | — | %
Biotech | — |  |  | — | % |  | — |  |  | — | %
Corporate and other | — |  |  | — | % |  | — |  |  | — | %
Total gross profit | $ | 2,591 |  |  | 47.0 | % |  | $ | — |  |  | — | %

Revenue
Revenue increased by approximately $5.5 million for the 13 weeks ended March 29, 2025, as compared to the 13 weeks ended March 30, 2024. The increase is due to the acquisition of ALT5 Subsidiary during May 2024.
Gross Profit
Gross profit increased by approximately $2.6 million for the 13 weeks ended March 29, 2025, as compared to the 13 weeks ended March 30, 2024. The increase is due to the acquisition of ALT5 Subsidiary during May 2024.
Selling, General and Administrative Expense
Selling, general and administrative expenses increased by approximately $3.0 million for the 13 weeks ended March 29, 2025, as compared to the 13 weeks ended March 30, 2024, primarily due to the acquisition of ALT5 Subsidiary during May 2024.
Interest Expense, net
Interest expense, net increased by approximately $470,000 for the 13 weeks ended March 29, 2025, as compared to the 13 weeks ended March 30, 2024 primarily due to the acquisition of ALT5 Subsidiary during May 2024.
Unrealized Loss on Marketable Securities
Unrealized loss on marketable securities for the 13 weeks ended March 30, 2024 was approximately $190,000. An unrealized gain or loss on marketable securities was recorded to mark to fair value securities received in connection to the sale of GeoTraq. No such unrealized gain or loss on marketable was recorded during the 13 weeks ended March 29, 2025.
Segment Performance
We report our business in the following segments: Biotechnology and discontinued operations. We expect revenues and profits for our biotechnology segment to be driven by the development of pharmaceuticals that treat the root cause of pain
28

Table of Contents
but are non-opioid painkillers. We include Corporate expenses within the Biotechnology segment. As discussed above, we sold our Recycling segment in March 2023, and detail its results as discontinued operations below.
Operating loss by operating segment, is defined as loss before net interest expense, other income and expense, provision for income taxes ($000’s).

| 13 Weeks Ended March 29, 2025 |  | 13 Weeks Ended March 30, 2024
| Fintech |  | Biotechnology |  | Corporate and Other |  | Total |  | Fintech |  | Biotechnology |  | Corporate and Other |  | Total
Revenue | $ | 5,514 |  |  | $ | — |  |  | $ | — |  |  | $ | 5,514 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |
Cost of revenue | 2,923 |  |  | — |  |  | — |  |  | 2,923 |  |  | — |  |  | — |  |  | — |  |  | — |
Gross profit | 2,591 |  |  | — |  |  | — |  |  | 2,591 |  |  | — |  |  | — |  |  | — |  |  | — |
Selling, general and administrative expense | 2,953 |  |  | 540 |  |  | 1,268 |  |  | 4,761 |  |  | — |  |  | 701 |  |  | 1,105 |  |  | 1,806 |
Operating loss | $ | (362) |  |  | $ | (540) |  |  | $ | (1,268) |  |  | $ | (2,170) |  |  | $ | — |  |  | $ | (701) |  |  | $ | (1,105) |  |  | $ | (1,806) |

Fintech Segment
Our Fintech segment consists of ALT5 Subsidiary, which was acquired during May 2024. Revenue for the 13 weeks ended March 29, 2025 was approximately $5.5 million, and gross margin percentage was 47.0%. Operating loss for the fiscal year ended 13 weeks ended March 29, 2025 was approximately $360,000.
Biotechnology Segment
Our Biotech segment generated no revenue for the for the 13 weeks ended March 29, 2025 and the 13 weeks ended March 30, 2024. Selling, general and administrative expenses increased primarily due to increased amortization costs relating to the Soin intangibles.
Corporate and Other Segment
Our Corporate and Other segment generated no revenue for the for the 13 weeks ended March 29, 2025 and the 13 weeks ended March 30, 2024. Selling, general and administrative expenses increased primarily due to increased costs for legal and other professional services.
Adjusted EBITDA Reconciliation
The following table presents a reconciliation of net income to Adjusted EBITDA for the 13 weeks ended March 29, 2025 and March 30, 2024 (in 000's):

| For the 13 Weeks Ended
| March 29, 2025 |  | March 30, 2024
Net income (loss) | $ | (2,861) |  |  | $ | (2,144) |
Depreciation and amortization | 1,210 |  |  | 639 |
Stock-based compensation | — |  |  | 345 |
Interest expense, net | 720 |  |  | 252 |
Income tax expense (benefit) | 285 |  |  | (75) |
Unrealized loss on marketable securities | — |  |  | 190 |
Unrealized Gain on exchange transactions | 87 |  |  | — |
Realized Gain on exchange transactions | 308 |  |  | — |
Other nonrecurring charges | 89 |  |  | 300 |
Adjusted EBITDA | $ | (162) |  |  | $ | (493) |

Adjusted EBITDA increased by approximately $0.3 million, or 67.1%, for the 13 weeks ended March 29, 2025, as compared to the prior year period. The increase was primarily due to the results of operations, as discussed above.
29

Table of Contents
Liquidity and Capital Resources
Overview
As of March 29, 2025, our cash on hand was $10.8 million. We intend to raise funds to support future development of JAN 123 either through capital raises or structured arrangements, which would include effectuating our previously announced intention to capitalize a subsidiary with certain of our biotechnology assets, acquire an additional biotechnology asset, and then engage in a financing of that subsidiary. The short-term intended result of that series of transactions would be for us to own a controlling interest in that subsidiary, but to decouple it from us so that it would operate on a stand-alone basis, although its financial statements would continue to be consolidated with ours for as long as we have a controlling interest.
Our ability to continue as a going concern is dependent upon the success of future capital raises or structured settlements and cash flows from the acquisition of ALT5 Subsidiary to fund the required testing to obtain FDA approval of JAN 123, as well as to fund our day-to-day operations. The accompanying financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. While we will actively pursue these additional sources of financing, management cannot make any assurances that such financing will be secured.
Cash Flows
During the 13 weeks ended March 29, 2025, cash used in operations was approximately $1.5 million, compared to cash provided by operations of approximately $544,000 during the 13 weeks ended March 30, 2024. The decrease in cash was primarily due to results of operations as discussed above.
Cash used in investing activities was $0 for the 13 weeks ended March 29, 2025 and the 13 weeks ended March 30, 2024.
Cash provided by financing activities was $1.5 million for the 13 weeks ended March 29, 2025, and relates to proceeds received from the issuance of notes payable, as well as warrants converted to our common stock, partially offset by cash paid for notes payable. Cash used in financing activities was approximately $600,000 for the 13 weeks ended March 30, 2024, and relates to proceeds received from warrants converted to our common stock.
Sources of Liquidity
We acknowledge that we continue to face a challenging competitive environment as we continue to focus on our overall profitability, including managing expenses. We reported a net loss of approximately $2.1 million for the 13 weeks ended March 29, 2025, and a net loss of approximately $2.9 million for the 13 weeks ended March 30, 2024, primarily due to increased costs associated with the acquisition ALT5 Subsidiary. Additionally, the Company has total current assets of approximately $31.8 million and total current liabilities of approximately $38.2 million resulting in a net negative working capital of approximately $6.4 million. Cash used in operations was approximately $1.5 million.
Future Sources of Cash; Phase 2b Trials, New Acquisitions, Products, and Services
We may require additional debt financing and/or capital to finance new acquisitions, conduct our Phase IIb clinical trials, or consummate other strategic investments in our business. No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Market Risk and Impact of Inflation
Interest Rate Risk. We do not believe there is any significant risk related to interest rate fluctuations on our short and long-term fixed rate debt.
We do not hold any derivative financial instruments, nor do we hold any securities for trading or speculative purposes.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Evaluation of Disclosure control and Procedures. We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded,
30

Table of Contents
processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure..
Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of March 29, 2025, the period covered in this report, our disclosure controls and procedures were not effective because of the material weaknesses discussed below.
In light of the conclusion that our internal disclosure controls are ineffective as of March 29, 2025, we have applied procedures and processes as necessary to ensure the reliability of our financial reporting in regard to this Quarterly Report. Accordingly, the Company believes, based on its knowledge, that: (i) this Quarterly Report does not contain any untrue statement of a material fact or omit a material fact; and (ii) the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects our financial condition, results of operations and cash flows as of and for the periods presented in this Quarterly Report.
Management’s Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of March 29, 2025. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in 2013 regarding Internal Control – Integrated Framework. Based on our assessment using those criteria, our management concluded that our internal control over financial reporting was not effective as of March 29, 2025.
Management noted material weaknesses in internal control when conducting their evaluation of internal control as of March 29, 2025. (1) Insufficient written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act; and (2) Insufficient resources to maintain adequate segregation of duties and maintain its internal control environment.
These material weaknesses remained outstanding as of the filing date of this Form 10-Q and management is currently working to remedy these outstanding material weaknesses.
The Company’s management, including the Company’s CEO and CFO, does not expect that the Company’s disclosure controls and procedures or the Company’s internal controls over financial reporting will prevent or detect all error and all fraud. A control system, regardless of how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. These inherent limitations include the following: judgements in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes, controls can be circumvented by individuals, acting alone or in collusion with each other, or by management override, the design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
Changes in Internal Control Over Financial Reporting. There were no changes in the Company’s internal control over financial reporting during the fiscal year ended March 29, 2025 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
31

Table of Contents
PART II. Other Information
Item 1. Legal Proceedings
The information in response to this item is included in Note 13, Commitments and Contingencies, to the Consolidated Financial Statements included in Part I, Item 1, of this Form 10-Q.
Item 1A. Risk Factors
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. However, in light of the SEC Complaint, the Company provides the following additional risk factors, which supplements the risk factors previously disclosed by the Company in Part I, Item 1A, Risk Factors, of the 2024 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of funds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information.
None.
Item 6. Exhibits.
Index to Exhibits
32

Table of Contents

Exhibit Number |  | Exhibit Description |  | Form |  | File Number |  | Exhibit Number |  | Filing Date
10.120 | * | Form of Securities Purchase Agreement with Mswipe Technologies, Inc., dated May 9, 2025. |  |  |  |  |  |  |  |
10.121 | * | Form of a Promissory Note in favor of Dr. Peter Francis Lue, dated May 9, 2025. |  |  |  |  |  |  |  |
10.122 | * | Form of a Common Stock Purchase Warrant, dated May 9, 2025. |  |  |  |  |  |  |  |
10.123 | * | Form of a Common Stock Purchase Warrant, dated May 9, 2025. |  |  |  |  |  |  |  |
10.124 | * | Form of a Common Stock Purchase Warrant, dated May 9, 2025. |  |  |  |  |  |  |  |
10.125 | * | Form of a Covenant Against Competition, dated May 9, 2025. |  |  |  |  |  |  |  |
10.126 | * | Form of a Promissory Note in favor of Peter Karam, dated May 9, 2025. |  |  |  |  |  |  |  |
31.1 | * | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
31.2 | * | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
32.1 | * | Certification of the President and Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
32.2 | * | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
101.INS | * | Inline XBRL Instance Document |  |  |  |  |  |  |  |
101.SCH | * | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |  |  |  |
101.CAL | * | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |  |  |  |
101.DEF | * | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  |  |  |  |
101.LAB | * | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  |  |  |  |
101.PRE | * | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |  |  |  |
104 |  | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |  |  |  |  |  |  |  |

33

Table of Contents
________________________
*Filed herewith.
34

Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on our behalf by the undersigned, thereunto duly authorized.

|  | JanOne Inc.
|  | (Registrant)
Date: | May 13, 2025 | By: | /s/ Peter Tassiopoulos
|  |  | Peter Tassiopoulos
|  |  | Chief Executive Officer
|  |  | (Principal Executive Officer)
Date: | May 13, 2025 | By: | /s/ Virland A. Johnson
|  |  | Virland A. Johnson
|  |  | Chief Financial Officer
|  |  | (Principal Financial and Accounting Officer)

35